Skip header and navigation

Refine By

   MORE

13 records – page 1 of 2.

Anticholinergic burden and dry mouth among Finnish, community-dwelling older adults.

https://arctichealth.org/en/permalink/ahliterature294919
Source
Gerodontology. 2018 Mar; 35(1):3-10
Publication Type
Journal Article
Date
Mar-2018
Author
Antti Tiisanoja
Anna-Maija Syrjälä
Kaija Komulainen
Pasi Lampela
Sirpa Hartikainen
Heidi Taipale
Matti Knuuttila
Pekka Ylöstalo
Author Affiliation
Unit of Oral Health Sciences Research, University of Oulu, Oulu, Finland.
Source
Gerodontology. 2018 Mar; 35(1):3-10
Date
Mar-2018
Language
English
Publication Type
Journal Article
Keywords
Aged
Aged, 80 and over
Cholinergic Antagonists - adverse effects - therapeutic use
Finland - epidemiology
Humans
Independent living
Male
Poisson Distribution
Saliva - secretion
Xerostomia - chemically induced - epidemiology
Abstract
The aim was to study whether the anticholinergic burden of drugs is related to xerostomia and salivary secretion among community-dwelling elderly people.
Anticholinergic drugs have been shown to be a risk factor for dry mouth, but little is known about the effects of cumulative exposure to anticholinergic drugs measured by anticholinergic burden on salivary secretion or xerostomia.
The study population consisted of 152 community-dwelling, dentate, non-smoking, older people from the Oral Health GeMS study. The data were collected by interviews and clinical examinations. Anticholinergic burden was determined using the Anticholinergic Drug Scale (ADS). A Poisson regression model with robust error variance was used to estimate relative risks (RR) with 95% confidence intervals (CI 95%).
Participants with a high-anticholinergic burden (ADS = 3) were more likely to have xerostomia (RR: 3.17; CI: 1.44-6.96), low-unstimulated salivary flow (
PubMed ID
28940566 View in PubMed
Less detail

Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease - exposure-matched cohort study.

https://arctichealth.org/en/permalink/ahliterature283663
Source
BMC Geriatr. 2016 Dec 01;16(1):204
Publication Type
Article
Date
Dec-01-2016
Author
Anna-Maija Tolppanen
Heidi Taipale
Antti Tanskanen
Jari Tiihonen
Sirpa Hartikainen
Source
BMC Geriatr. 2016 Dec 01;16(1):204
Date
Dec-01-2016
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - epidemiology
Causality
Cohort Studies
Comorbidity
Demography
Female
Finland - epidemiology
Hip Fractures - epidemiology - mortality
Humans
Incidence
Independent Living - statistics & numerical data
Male
Proportional Hazards Models
Risk factors
Socioeconomic Factors
Abstract
Dementia, with Alzheimer's disease (AD) being the most common form, is a major hip fracture risk factor, but currently it is not known whether the same factors predict hip fracture among persons with and without dementia/AD. We compared the predictors of hip fracture and mortality after hip fracture in persons with and without AD.
An exposure-matched cohort of all community-dwellers of Finland who received a new clinically verified AD diagnosis in 2005-2011 and had no history of previous hip fracture (N = 67,072) and an age, sex, and region-matched cohort of persons without AD (N = 67,072). Associations between sociodemographic characteristics, comorbidities and medications and risk of hip fracture and mortality after hip fracture were assessed with Cox regression.
As expected, the incidence of hip fractures in 2005-2012 (2.19/100 person-years vs 0.90/100 person-years in the non-AD cohort), as well as mortality after hip fracture (29/100 person-years vs 23/100 person-years in the non-AD cohort) were higher in the AD cohort. This difference was evident regardless of the risk factors. Mental and behavioural disorders (adjusted hazard ratio; HR 95% confidence interval CI: 1.16, 1.09-1.24 and 1.71, 1.52-1.92 in the AD and non-AD-cohorts), antipsychotics (1.12, 1.04-1.20 and 1.56, 1.38-1.76 for AD and non-AD-cohorts) and antidepressants (1.06, 1.00-1.12 and 1.34 1.22-1.47 for AD and non-AD-cohorts) were related to higher, and estrogen/combination hormone therapy (0.87, 0.77-0.9 and 0.79, 0.64-0.98 for AD and non-AD-cohorts) to lower hip fracture risk in both cohorts. Stroke (1.42, 1.26-1.62), diabetes (1.13, 0.99-1.28), active cancer treatment (1.67, 1.22-2.30), proton pump inhibitors (1.14, 1.05-1.25), antiepileptics (1.27, 1.11-1.46) and opioids (1.10, 1.01-1.19) were associated with higher hip fracture risk in the non-AD cohort. Similarly, the associations between mortality risk factors (age, sex, several comorbidities and medications) were stronger in the non-AD cohort.
AD itself appears to be such a significant risk factor for hip fracture, and mortality after hip fracture, that it overrules or diminishes the effect of other risk factors. Thus, it is important to develop and implement preventive interventions that are suitable and effective in this population.
Notes
Cites: Arch Gerontol Geriatr. 2014 Jul-Aug;59(1):1-624657007
Cites: Eur Neuropsychopharmacol. 2015 Oct;25(10):1706-1326233607
Cites: J Orthop Sci. 2007 Mar;12(2):113-717393264
Cites: Injury. 2015 Apr;46(4):713-825627481
Cites: Osteoporos Int. 2014 Dec;25(12):2817-2425092059
Cites: Injury. 2015;46(6):1028-3525813734
Cites: Methods Inf Med. 2007;46(5):558-6617938779
Cites: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD00337618254018
Cites: BMJ. 2013 Oct 29;347:f623424169944
Cites: J Am Med Dir Assoc. 2014 May;15(5):334-4124524851
Cites: Drugs Aging. 2012 Jan 1;29(1):15-3022191720
Cites: Mol Neurobiol. 2016 Apr 12;:null27072352
Cites: Ann Pharmacother. 2012 Jul-Aug;46(7-8):917-2822811347
Cites: Cochrane Database Syst Rev. 2013 Mar 28;(3):CD00772623543555
Cites: Drugs Aging. 2014 Jul;31(7):547-5324825617
Cites: Clin Epidemiol. 2016 Oct 11;8:363-37127785101
Cites: Cochrane Database Syst Rev. 2012 Sep 12;(9):CD00714622972103
Cites: Injury. 2013 Dec;44(12):1930-323688407
Cites: QJM. 2007 Sep;100(9):539-4517693418
Cites: Drugs Aging. 2011 Nov 1;28(11):913-2522054232
Cites: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD00452318254053
Cites: Sci Rep. 2016 Mar 18;6:2336026987933
Cites: Ann Med. 2011 Jun;43 Suppl 1:S39-4621639716
Cites: BMJ Open. 2016 Jul 13;6(7):e01210027412109
Cites: Alzheimers Dement. 2016 Apr;12 (4):459-50927570871
Cites: Clin Geriatr Med. 2014 May;30(2):175-8124721358
Cites: J Clin Psychopharmacol. 2014 Aug;34(4):435-4024875073
Cites: Clin Epidemiol. 2013 Aug 07;5:277-8523950660
Cites: Osteoporos Int. 2016 Oct;27(10):2935-4427105645
Cites: Scand J Public Health. 2012 Aug;40(6):505-1522899561
Cites: J Clin Psychopharmacol. 2012 Apr;32(2):218-2422367651
Cites: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD00444115674948
Cites: Osteoporos Int. 2005 Dec;16(12):2185-9416177836
Cites: Arch Phys Med Rehabil. 2015 Jul;96(7):1215-2125701641
Cites: Osteoporos Int. 2014 Jan;25(1):105-2024013517
Cites: J Gerontol A Biol Sci Med Sci. 2007 Oct;62(10):1172-8117921433
Cites: BMC Med Inform Decis Mak. 2015 Mar 25;15:2125890003
Cites: Age Ageing. 2011 Jan;40(1):49-5421087990
Cites: Br J Psychiatry. 2015 Nov;207 (5):444-926450581
Cites: Neurology. 1984 Jul;34(7):939-446610841
Cites: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD00115518253985
PubMed ID
27908278 View in PubMed
Less detail

Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease.

https://arctichealth.org/en/permalink/ahliterature300475
Source
Eur J Clin Pharmacol. 2019 Mar; 75(3):417-425
Publication Type
Journal Article
Date
Mar-2019
Author
Reetta Kettunen
Heidi Taipale
Anna-Maija Tolppanen
Antti Tanskanen
Jari Tiihonen
Sirpa Hartikainen
Marjaana Koponen
Author Affiliation
School of Pharmacy, University of Eastern Finland, PO Box 1627, 70211, Kuopio, Finland.
Source
Eur J Clin Pharmacol. 2019 Mar; 75(3):417-425
Date
Mar-2019
Language
English
Publication Type
Journal Article
Keywords
Age Factors
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy
Antidepressive Agents - administration & dosage - therapeutic use
Antipsychotic Agents - administration & dosage - therapeutic use
Cohort Studies
Female
Finland
Humans
Independent living
Male
Proportional Hazards Models
Registries
Sex Factors
Time Factors
Abstract
To study how long antidepressants initiated after diagnoses of Alzheimer's disease (AD) were used and factors associated with discontinuation of use among persons with Alzheimer's disease (AD). In addition, differences in duration of use between the antidepressants groups were compared.
Register-based Medication use and Alzheimer's disease (MEDALZ) cohort included 70,718 community-dwelling people with AD who were diagnosed during the years 2005-2011. For this study, the new antidepressant users were included after 1-year washout period (N?=?16,501; 68.6% females, mean age 80.9). The duration of antidepressant use was modeled with the PRE2DUP method. Factors associated with treatment discontinuation were assessed with Cox proportional hazard models and included age, gender, comorbid conditions and concomitant medications.
Median duration of the new antidepressant use period was 309 days (IQR 93-830). For selective serotonin reuptake inhibitor (SSRI) use, the median duration was 331 days (IQR 101-829), for mirtazapine 202 days (IQR 52-635), and for serotonin and norepinephrine reuptake inhibitors (SNRIs) 134 days (IQR 37-522). After 1-year follow-up, 40.8% had discontinued antidepressant use, 54.6% after 2 years and 64.1% after 3 years. Factors associated with treatment discontinuation were age over 85, male gender, diabetes, and use of memantine, opioids, and antiepileptics whereas benzodiazepines and related drugs and antipsychotic use were inversely associated with discontinuation.
Antidepressants are used for long-term among people with AD. Need and indication for antidepressant use should be assessed regularly as evidence on their efficacy for behavioral and psychological symptoms of dementia is limited.
PubMed ID
30413841 View in PubMed
Less detail

The effect of comprehensive geriatric assessment on anticholinergic exposure assessed by four ranked anticholinergic lists.

https://arctichealth.org/en/permalink/ahliterature283602
Source
Arch Gerontol Geriatr. 2017 Jan - Feb;68:195-201
Publication Type
Article
Author
Pasi Lampela
Heidi Taipale
Piia Lavikainen
Sirpa Hartikainen
Source
Arch Gerontol Geriatr. 2017 Jan - Feb;68:195-201
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Cholinergic Antagonists
Drug Utilization - statistics & numerical data
Female
Finland
Follow-Up Studies
Geriatric Assessment - methods
Humans
Independent living
Male
Outcome Assessment (Health Care)
Abstract
Older people often use multiple drugs, and some of them have anticholinergic activity. Anticholinergic drugs may cause adverse reactions, and therefore their use should be limited. To identify anticholinergic load, several ranked lists with different drugs and scoring systems have been developed and used widely in research. We investigated, if a comprehensive geriatric assessment (CGA) decreased the anticholinergic drug score in a 4-year period. We used four different anticholinergic ranked lists to determine the anticholinergic score and to describe how the results differ depending on the list used.
We analyzed data from population-based intervention study, in which a random sample of 1000 persons aged =75 years were randomized to either an intervention group or a control group. Those in the intervention group underwent CGA including medication assessment annually between 2004 and 2007. Current medication use was assessed annually. The anticholinergic load was calculated by using four ranked lists of anticholinergic drugs (Boustani's, Carnahan's, Chew's and Rudolph's) for each person and for each year.
CGA had no statistically significant effect on anticholinergic exposure during the 4-year follow-up, but improvements towards more appropriate medication use were observed especially in the intervention group. However, age, gender and functional comorbidity index were associated to higher anticholinergic exposure, depending on the list used.
Repeated CGAs may result as more appropriate anticholinergic medication use. The selection of the list may affect the results and therefore the selection of the list is important.
PubMed ID
27837709 View in PubMed
Less detail

Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease.

https://arctichealth.org/en/permalink/ahliterature300965
Source
Int Psychogeriatr. 2018 07; 30(7):947-956
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
07-2018
Author
Aleksi Hamina
Piia Lavikainen
Antti Tanskanen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Heidi Taipale
Author Affiliation
Kuopio Research Centre of Geriatric Care,University of Eastern Finland,Kuopio,Finland.
Source
Int Psychogeriatr. 2018 07; 30(7):947-956
Date
07-2018
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Aged
Alzheimer Disease - drug therapy - epidemiology - psychology
Analgesics, Opioid - administration & dosage
Antipsychotic Agents - therapeutic use
Benzodiazepines - therapeutic use
Cognition - drug effects
Female
Finland - epidemiology
Humans
Independent Living - psychology - statistics & numerical data
Interrupted Time Series Analysis
Male
Medication Adherence - psychology - statistics & numerical data
Pharmacoepidemiology
Prevalence
Registries - statistics & numerical data
Risk assessment
Risk factors
Abstract
ABSTRACTBackground:We analyzed the impact of opioid initiation on the prevalence of antipsychotic and benzodiazepine and related drug (BZDR) use among community-dwelling persons with Alzheimer's disease (AD).
We utilized the register-based Medication use and Alzheimer's disease (MEDALZ) cohort for this study. We included all community-dwelling persons diagnosed with AD during 2010-2011 in Finland initiating opioid use (n = 3,327) and a matched cohort of persons not initiating opioids (n = 3,325). Interrupted time series analyses were conducted to compare the prevalence of antipsychotic and BZDR use in 30-day periods within six months before opioid initiation to 30-day periods six months later.
Before opioid initiation, prevalence of antipsychotic use among opioid initiators was 13.3%, 18.3% at opioid initiation, and 17.3% six months later. Prevalences of BZDR use were 27.1% six months prior, 28.9% at opioid initiation, and 26.9% six months later. After opioid initiation, antipsychotic and BZDR use declined by 0.3 percentage points (pps, 95% confidence interval 0.1-0.5) and 0.4 pps (0.2-0.7) per month, respectively, until the end of the follow-up. Compared to persons not initiating opioid use, opioid initiation immediately resulted in an increase in prevalence of 1.9 pps (0.9-2.8) for antipsychotics and of 1.6 pps (0.9-2.2) for BZDR use. However, in total there was a comparative decrease of 0.5 pps (0.3-0.8) per month for antipsychotics and of 0.4 pps (0.2-0.6) for BZDR use until the end of the follow-up.
Our results suggest that opioid initiation may reduce antipsychotic and BZDR use among persons with AD.
PubMed ID
29559009 View in PubMed
Less detail

Incidence of antidepressant use in community-dwelling persons with and without Alzheimer's disease: 13-year follow-up.

https://arctichealth.org/en/permalink/ahliterature295340
Source
Int J Geriatr Psychiatry. 2017 01; 32(1):94-101
Publication Type
Journal Article
Date
01-2017
Author
Arto Puranen
Heidi Taipale
Marjaana Koponen
Antti Tanskanen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Author Affiliation
Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland.
Source
Int J Geriatr Psychiatry. 2017 01; 32(1):94-101
Date
01-2017
Language
English
Publication Type
Journal Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - complications - drug therapy - psychology
Antidepressive Agents - administration & dosage - adverse effects - therapeutic use
Depression - complications - drug therapy - psychology
Female
Finland - epidemiology
Follow-Up Studies
Humans
Incidence
Independent living
Male
Middle Aged
Serotonin Uptake Inhibitors - administration & dosage - therapeutic use
Time Factors
Abstract
The study aimed to investigate the incidence of antidepressant use in persons with and without Alzheimer's disease (AD) from 9?years before to 4?years after AD diagnosis and to examine the incidence of different antidepressant groups.
We used register-based data from the Medication use and Alzheimer's disease cohort including all Finnish persons diagnosed with AD in 2005-2011 with their age-matched and gender-matched comparison persons without AD. In this study, 62,104 persons with AD and 62,104 comparison persons were included. Data on dispensed antidepressants during 1995-2012 were collected from the Prescription Register. A 1-year washout period was utilized to measure the rate of new antidepressant users every 6-month period starting from 9?years before and until 4?years after the AD diagnoses. The incidence rate between persons with and without AD was compared with Poisson regression.
The incidence of antidepressant use in persons with AD was higher during the whole study period compared with that in persons without AD. The incidence rate was highest at 6?months after AD diagnosis (incidence rate ratio?=?5.22, 95% confidence interval 4.77-5.72). Selective serotonin reuptake inhibitors were the most frequently initiated group (61.3% of initiations in persons with AD).
The incidence of antidepressant use was higher in persons with AD than in comparison persons, and it was not explained by history of hospital-treated psychiatric disorders. Widespread use of antidepressants in persons with AD is concerning as their efficacy is controversial and their use is associated with adverse events. Copyright © 2016 John Wiley & Sons, Ltd.
PubMed ID
26924266 View in PubMed
Less detail

Incidence of Bisphosphonate Use in Relation to Diagnosis of Alzheimer's Disease in Community-Dwelling Persons.

https://arctichealth.org/en/permalink/ahliterature294596
Source
J Am Geriatr Soc. 2016 09; 64(9):e48-9
Publication Type
Letter
Date
09-2016

Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer's disease.

https://arctichealth.org/en/permalink/ahliterature270647
Source
Int Clin Psychopharmacol. 2015 Jul;30(4):202-8
Publication Type
Article
Date
Jul-2015
Author
Heidi Taipale
Marjaana Koponen
Antti Tanskanen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Source
Int Clin Psychopharmacol. 2015 Jul;30(4):202-8
Date
Jul-2015
Language
English
Publication Type
Article
Keywords
Age Factors
Aged
Aged, 80 and over
Alzheimer Disease - diagnosis - epidemiology - psychology
Benzodiazepines - administration & dosage - adverse effects
Case-Control Studies
Cognition - drug effects
Comorbidity
Drug Administration Schedule
Drug Prescriptions
Drug Utilization Review
Female
Finland - epidemiology
Humans
Inappropriate Prescribing
Independent living
Male
Practice Patterns, Physicians'
Prevalence
Registries
Risk assessment
Risk factors
Sex Factors
Time Factors
Treatment Outcome
Abstract
The aim of this study was to investigate the prevalence of benzodiazepine and related drug (BZDR) use, especially long-term use, and associated factors among community-dwelling individuals with and without Alzheimer's disease (AD). We utilized data from the MEDALZ-2005 cohort, which includes all community-dwelling individuals diagnosed with AD in Finland at the end of 2005 and matched comparison individuals without AD. Register-based data included prescription drug purchases, comorbidities, and hospital discharge diagnoses. In this study, 24,966 individuals with AD and 24,985 individuals without AD were included. During the 4-year follow-up, we found that 45% (N = 11,312) of individuals with AD and 38% (N = 9534) of individuals without AD used BZDRs. The prevalence of long-term (= 180 days) BZDR use was more common among individuals with AD (30%) than individuals without AD (26%). The median durations of the first long-term use periods of BZDRs were 1.5 and 2 years for individuals with and without AD, respectively. Factors associated with long-term BZDR use included female sex, AD, schizophrenia, bipolar disorder, depression, coronary artery disease, and asthma/chronic obstructive pulmonary disease. The high prevalence of long-term BZDR use among individuals with AD is especially a cause for concern because long-term use may further impair cognition and may be associated with serious adverse events.
PubMed ID
26011780 View in PubMed
Less detail

Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study.

https://arctichealth.org/en/permalink/ahliterature287023
Source
Pain. 2017 Feb;158(2):252-260
Publication Type
Article
Date
Feb-2017
Author
Aleksi Hamina
Heidi Taipale
Antti Tanskanen
Anna-Maija Tolppanen
Niina Karttunen
Liisa Pylkkänen
Jari Tiihonen
Sirpa Hartikainen
Source
Pain. 2017 Feb;158(2):252-260
Date
Feb-2017
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - complications
Analgesics, Opioid - therapeutic use
Cohort Studies
Female
Finland - epidemiology
Humans
Independent living
Male
Pain - drug therapy - epidemiology - etiology
Prevalence
Registries - statistics & numerical data
Abstract
Persons with Alzheimer disease (AD) commonly present with chronic nonmalignant pain, but long-term use of opioids among this population has not been studied previously. Our aim was to investigate the prevalence of long-term (=180 days) use of opioids for nonmalignant pain and associated factors among community-dwelling persons with AD and to compare the prevalence with a matched cohort without AD. The Medication use and Alzheimer's disease (MEDALZ) cohort was used for this study, comprising all community-dwelling persons diagnosed with AD in Finland during 2005 to 2011 and their matched comparison persons without AD. After exclusion of persons with active cancer treatment, 62,074 persons with and 62,074 persons without AD were included in this study. Data were collected from nationwide registers. Opioids were used by 13,111 persons with and by 16,659 without AD. Overall long-term opioid use was more common among persons without AD (8.7%) than among persons with AD (7.2%, P
PubMed ID
28092324 View in PubMed
Less detail

Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.

https://arctichealth.org/en/permalink/ahliterature291615
Source
Eur J Clin Pharmacol. 2017 Sep; 73(9):1149-1158
Publication Type
Journal Article
Date
Sep-2017
Author
Heidi Juntunen
Heidi Taipale
Antti Tanskanen
Anna-Maija Tolppanen
Jari Tiihonen
Sirpa Hartikainen
Miia Tiihonen
Author Affiliation
Kuopio Research Centre of Geriatric Care, University of Eastern Finland, P.O.B 1627, -70211, Kuopio, FI, Finland.
Source
Eur J Clin Pharmacol. 2017 Sep; 73(9):1149-1158
Date
Sep-2017
Language
English
Publication Type
Journal Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy
Diphosphonates - therapeutic use
Drug Utilization - statistics & numerical data
Female
Fibrinolytic Agents - therapeutic use
Finland
Humans
Independent Living - statistics & numerical data
Male
Models, Theoretical
Proton Pump Inhibitors - therapeutic use
Registries
Serotonin Uptake Inhibitors - therapeutic use
Abstract
The aim of this study is to determine the prevalence of use and long-term use (=180 days) of proton pump inhibitors (PPIs) and associated factors among community-dwellers with and without Alzheimer's disease (AD).
MEDALZ cohort encompassed all persons who received a verified diagnosis of AD in Finland during the years 2005-2011 and their age-, sex-, and region of residence-matched comparison persons, including 69,353 persons with and 69,353 persons without AD. Data was derived from several Finnish administrative registers. A mathematical modelling method, PRE2DUP, was used for converting dispensing data to drug use periods (when regular PPI use started and ended). Morbid conditions and concomitant drugs associated with use and long-term use of PPIs were assessed with logistic regression models.
Use of PPIs was more common among comparison persons than persons with AD (39.0 and 35.8%, respectively, p 
Notes
Cites: Am J Med. 2010 Jun;123(6):496-501 PMID 20569750
Cites: Br J Clin Pharmacol. 2004 Jan;57(1):6-14 PMID 14678335
Cites: Drugs Aging. 2014 Apr;31(4):263-82 PMID 24634248
Cites: Int Psychogeriatr. 2016 Jul;28(7):1059-65 PMID 26744954
Cites: Eur J Intern Med. 2017 Jan;37:19-24 PMID 27784575
Cites: Eur J Clin Pharmacol. 2008 Oct;64(10):935-51 PMID 18679668
Cites: Aliment Pharmacol Ther. 2016 Jul;44(1):78-87 PMID 27137875
Cites: J Am Geriatr Soc. 2009 Aug;57(8):1331-46 PMID 19573219
Cites: Arch Med Res. 2012 Nov;43(8):600-8 PMID 23159715
Cites: Clin Epidemiol. 2016 Oct 11;8:363-371 PMID 27785101
Cites: Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):9-16 PMID 27859947
Cites: Res Social Adm Pharm. 2017 Mar - Apr;13(2):358-363 PMID 27033427
Cites: BMC Med. 2016 Nov 9;14 (1):179 PMID 27825371
Cites: Eur Respir J. 2017 Mar 15;49(3):null PMID 28298398
Cites: Eur J Clin Pharmacol. 2007 Nov;63(11):1069-74 PMID 17712552
Cites: JAMA Neurol. 2016 Apr;73(4):410-6 PMID 26882076
Cites: Eur Arch Psychiatry Clin Neurosci. 2015 Aug;265(5):419-28 PMID 25341874
Cites: BMJ Open. 2016 Jul 13;6(7):e012100 PMID 27412109
Cites: J Am Geriatr Soc. 2016 Dec;64(12 ):e291-e296 PMID 27996115
Cites: J Am Geriatr Soc. 2010 May;58(5):880-8 PMID 20406320
Cites: Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1079-87 PMID 27255671
Cites: Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):443-54 PMID 23998981
Cites: Ann Clin Biochem. 2013 Jul;50(Pt 4):315-29 PMID 23592803
Cites: BMC Med Inform Decis Mak. 2015 Mar 25;15:21 PMID 25890003
Cites: Age Ageing. 2013 Mar;42 Suppl 1:i1-57 PMID 23420266
Cites: Eur J Pain. 2017 Apr;21(4):658-667 PMID 27862681
Cites: Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1070-8 PMID 27184012
Cites: Scand J Prim Health Care. 2010 Sep;28(3):154-9 PMID 20586539
Cites: Drugs Aging. 2012 Aug 1;29(8):681-90 PMID 22775478
Cites: Therap Adv Gastroenterol. 2016 Sep;9(5):671-8 PMID 27582879
Cites: Drugs Aging. 2010 Apr 1;27(4):337-49 PMID 20359263
Cites: Neurology. 1984 Jul;34(7):939-44 PMID 6610841
Cites: Drugs Aging. 2010 Jul 1;27(7):545-58 PMID 20583849
PubMed ID
28577224 View in PubMed
Less detail

13 records – page 1 of 2.